About
Matisse Pharmaceuticals B.V. is a clinical-stage biopharmaceutical company developing therapies that neutralize extracellular cytotoxic histones; its lead program, isupartob sodium, is targeted at treating sepsis and septic shock. The company focuses on indications characterized by elevated extracellular histone levels and is progressing clinical development and regulatory interactions.
Explore Matisse Pharmaceuticals B.V.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.